Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Long-term immunogenicity and efficacy of the quadrivalent human papillomavirus vaccine in women with HIV: a longitudinal cohort study. Local targets link to admitted publications; unresolved targets remain external evidence.
The epidemiology of human papillomavirus infections
10.1016/j.jcv.2004.12.008 · 2005 · External reference
High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse)
2001 · External reference
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
10.1002/(sici)1096-9896(199909)189:1<12::aid-path431>3.0.co;2-f · 1999 · External reference
End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age
10.1038/bjc.2011.185 · 2011 · External reference
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
10.1016/s1470-2045(11)70286-8 · 2012 · External reference
Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil™ in adult women
10.1371/journal.pone.0083431 · 2013 · External reference
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women
10.1093/jnci/djp534 · 2010 · External reference
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18
10.1016/j.vaccine.2006.04.068 · 2006 · External reference
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial
10.1016/s0140-6736(17)31821-4 · 2017 · External reference
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
10.1016/s1470-2045(05)70101-7 · 2005 · External reference
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine
10.1016/j.vaccine.2008.09.073 · 2008 · External reference
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial
10.1016/s0140-6736(09)60691-7 · 2009 · External reference
Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four Nordic countries
10.1016/j.eclinm.2020.100401 · 2020 · External reference
Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors
2018 · External reference
The quadrivalent HPV vaccine is protective against genital warts: a meta-analysis
10.1186/s12889-020-08753-y · 2020 · External reference
HIV infection and survival among women with cervical cancer
10.1200/jco.2016.67.9613 · 2016 · External reference
HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine
10.1016/j.vaccine.2016.08.016 · 2016 · External reference
The efficacy of the quadrivalent human papillomavirus vaccine in girls and women living with human immunodeficiency virus
10.1093/cid/ciy575 · 2019 · External reference
Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in girls living with HIV
10.1097/inf.0000000000001874 · 2018 · External reference
Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the Linear array HPV genotyping test
10.1128/jcm.00104-06 · 2006 · External reference
Confirmatory real-time PCR assay for human papillomavirus (HPV) type 52 infection in anogenital specimens screened for HPV infection with the linear array HPV genotyping test
10.1128/jcm.01145-07 · 2007 · External reference
Fast stable restricted maximum likelihood and marginal likelihood estimation of semiparametric generalized linear models
10.1111/j.1467-9868.2010.00749.x · 2010 · External reference
Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging
10.1016/s1470-2045(15)70075-6 · 2015 · External reference
Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine—a combined analysis of five phase III clinical trials
10.1016/j.pvr.2017.03.002 · 2017 · External reference
Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials
10.1086/599988 · 2009 · External reference
Immunogenicity and safety of two versus three doses of 9-valent vaccine against Human papillomavirus (HPV) in women with HIV: the Papillon randomized trial
2025 · External reference
Population impact of South Africa's human papillomavirus (HPV) vaccination programme on HPV prevalence in adolescent girls with and without HIV: a repeat cross-sectional study
10.1016/s2214-109x(25)00525-x · 2026 · External reference
